1319197-00-6

Basic information

• Product Name: (2-(2-(tert-butylamino)-3-(1-hydroxy-5-(tetrahydro-2H-pyran-2-yloxy)pent-2-ynyl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone
• Synonyms: (2-(2-(tert-butylamino)-3-(1-hydroxy-5-(tetrahydro-2H-pyran-2-yloxy)pent-2-ynyl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone
• CAS NO: 1319197-00-6
• Molecular Weight: 569.744
• Mol File: 1319197-00-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2-(2-(tert-butylamino)-3-(1-hydroxy-5-(tetrahydro-2H-pyran-2-yloxy)pent-2-ynyl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2-(2-(tert-butylamino)-3-(1-hydroxy-5-(tetrahydro-2H-pyran-2-yloxy)pent-2-ynyl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone(1319197-00-6)
• EPA Substance Registry System: (2-(2-(tert-butylamino)-3-(1-hydroxy-5-(tetrahydro-2H-pyran-2-yloxy)pent-2-ynyl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone(1319197-00-6)

Safety Data

• Hazardous Substances Data: 1319197-00-6(Hazardous Substances Data)

Upstream product

• 1319196-98-9 2-(tert-butylamino)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline-3-carbaldehyde 
• 1308870-06-5 2-(tert-butylamino)-6-bromoquinoline-3-carbaldehyde 
• 73568-35-1 6-bromo-2-chloro-3-formylquinoline 
• 40365-61-5 2-(but-3-yn-1-yloxy)tetrahydropyran 
• 1319196-99-0 2-(tert-butylamino)-6-(2-methyl-6-(pyrrolidine-1-carbonyl)phenyl)quinoline-3-carbaldehyde 

Downstream Products

• 1319197-01-7 (2-(2-(tert-butylamino)-3-(1,5-dihydroxypentyl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 
• 1319194-50-7 (2-(2-amino-3-(tetrahydro-2H-pyran-2-yl)quinolin-6-yl)-3-methylphenyl)(pyrrolidin-1-yl)methanone 

Relevant articles and documents

AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B1, B2, B3, L, R1, R2, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).